Australia's Control Bionics hits over 1-month high on registration of device in UK
08/03/2024 04:44
** Shares of Control Bionics CBL.AX rise as much as 4% to
A$0.052, their highest level since Jan. 25
** Medical device co says its flagship product, the
NeuroNode, has been registered with the UK Medicines and
Healthcare Products Regulatory Agency
** NeuroNode is a wearable device that allows people with
limited or no physical movement to control computers,
communication devices, and other assistive technologies using
subtle muscle signals
** CBL heads for biggest weekly gain since July 2022, rising
23.8% so far
** Stock up ~9% YTD, as of last close
(Reporting by Neha Soni in Bengaluru)
((Neha.Soni@thomsonreuters.com))
Recent news on Control Bionics
See all newsBrief: Control Bionics Posts Full-Year Loss Attributable Of A$7.3 Million
Brief: Control Bionics Sees FY27 Revenue Growth Of 50% Over FY26
Brief: Control Bionics Says Medicare Billing Code Secured For Nextlevel Speech Devices
Brief: Control Bionics Receives UK MHRA Registration For Neurostrip
Australia's Control Bionics jumps after FDA listing for NeuroStrip device